Safety, Clinical Activity and Pharmacokinetics of Alflutinib (AST2818) in Advanced NSCLC Patients with EGFR T790M Mutation.
Journal of Thoracic Oncology(2020)
摘要
Alflutinib was clinically effective with an acceptable toxicity profile in advanced NSCLC patients (including those with CNS metastases) with EGFR T790M mutation. Further investigation is ongoing.
更多查看译文
关键词
Alflutinib,NSCLC,EGFR T790M mutation,Efficacy,Safety
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络